
    
      In this study, patients with type 2 diabetes who meet randomization criteria will be
      randomized to either liraglutide or placebo, with serial assessment of beta-cell function
      over 48 weeks follow-up. The hypothesis under study is whether liraglutide can preserve
      beta-cell function.
    
  